Next Article in Journal
Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study
Next Article in Special Issue
Increased Presentation of Diabetic Ketoacidosis and Changes in Age and Month of Type 1 Diabetes at Onset during the COVID-19 Pandemic in Spain
Previous Article in Journal
Cardiovascular Profile of South African Adults with Low-Level Viremia during Antiretroviral Therapy
Previous Article in Special Issue
Prevention of Peripheral Distal Polyneuropathy in Patients with Diabetes: A Systematic Review
 
 
Article
Peer-Review Record

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study

J. Clin. Med. 2022, 11(10), 2813; https://doi.org/10.3390/jcm11102813
by Sol Batule 1,†, Analía Ramos 1,†, Alejandra Pérez-Montes de Oca 1, Natalia Fuentes 1, Santiago Martínez 1, Joan Raga 2, Xoel Pena 2, Cristina Tural 2, Pilar Muñoz 2, Berta Soldevila 1, Nuria Alonso 1, Guillermo Umpierrez 3 and Manel Puig-Domingo 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2022, 11(10), 2813; https://doi.org/10.3390/jcm11102813
Submission received: 12 April 2022 / Revised: 10 May 2022 / Accepted: 12 May 2022 / Published: 16 May 2022
(This article belongs to the Special Issue The Prevention, Treatment, and Complications of Diabetes Mellitus)

Round 1

Reviewer 1 Report

The manuscript entitled “Comparison of glycemic variability and hypoglycemic events in hospitalized older adults treated with basal insulin plus vildagliptin and basal-bolus insulin regimen: A prospective randomized study” evaluated the efficacy and safety of two treatments for in-hospital blood glucose control in a small cohort of elderly people. Basal-DPP4i treatment was associated with hypoglycaemia less often when compared to basal-bolus treatment, as well as a lower coefficient of variation.   

 

Minor comments 

 

  • Why were patients not allocated to basal-vidagliptin and basal-bolus in a manner 1:1 rather than 44:50?
  • The authors reported the causes of hospitalization in 67% of the patients. What was the remaining cause of hospitalization in 33% of patients? Was there a difference in the causes of hospitalization between the groups?
  • Abstract section: Review the standard deviation of HbA1c (6.6%±19). Is it 1.9% instead of 19%?
  • Were the episodes of hypoglycaemia symptomatic or asymptomatic?

 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

Dear Authors,

  1. In my opinion conlsusions should be written as separate point and this point should be more extensive.
  2. In my opinion should be a part of test with inclusion critieria and their description

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

Dear Authors ,

  1. In my opinion text with inclusion and  exclusion critieria are incomplete and unreadable.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop